Noninvasive vascular therapy

• US 7,767,208 B2
• Filed: 07/13/2001
• Issued: 08/03/2010
• Est. Priority Date: 01/15/1999
• Status: Active Grant

• Current Assignee: Light Sciences Oncology, Inc.
• Original Assignee: Light Sciences Oncology, Inc.
• Inventors: Chen, James
• Primary Examiner(s): Canella; Karen A
• Application Number:
  US09/905,777
• Publication Number:
  US 20020127230A1
• Time in Patent Office: 3,308 Days
• Field of Search: 424/178.1, 604/20
• US Class Current: 424/181.1
• CPC Class Codes: A61B 18/1815 using microwaves
• CPC Class Codes: A61B 2090/378 using ultrasound
• CPC Class Codes: A61K 41/0057 Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
• CPC Class Codes: A61K 41/0071 PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
• CPC Class Codes: A61N 2005/0602 for treatment of blood vessels
• CPC Class Codes: A61N 2005/0604 Lungs and/or airways
• CPC Class Codes: A61N 2005/0609 Stomach and/or esophagus
• CPC Class Codes: A61N 2005/0651 Diodes
• CPC Class Codes: A61N 2005/0659 infrared
• CPC Class Codes: A61N 5/0601 Apparatus for use inside the body
• CPC Class Codes: A61N 5/062 Photodynamic therapy, i.e. excitation of an agent
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention is drawn to methods and compounds for transcutaneous photodynamic therapy (“PDT”) of a target tissue or compositions in a mammalian subject, which includes administering to the subject a therapeutically effective amount of a photosensitizing agent or a photosensitizing agent delivery system or prodrug, where the photosensitizing agent or photosensitizing agent delivery system or prodrug selectively binds to the target tissue; and irradiating at least a portion of the subject with light at a wavelength absorbed by the photosensitizing agent or if prodrug, by a prodrug product thereof, where the light is provided by a light source, and where the irradiation is at low fluence rate that results in the activation of the photosensitizing agent or prodrug product. These methods of transcutaneous PDT are useful in the treatment of specifically selected target tissues, such as: vascular endothelial tissue; abnormal vascular wall of tumors; tumors of the head and neck; tumors of the gastrointestinal tract; tumors of the liver; tumors of the esophopharyngeal; tumors of the lung; lymphoid tissue; lesions in the vascular system; bone marrow and tissue related to autoimmune disease.

Claims

1. A method for destroying or impairing target cells of a lesion in the vascular system in a mammalian subject, comprising:

administering to the subject a therapeutically effective amount of a photosensitizing agent, wherein the photosensitizing agent is conjugated to a ligand that selectively binds to an antigen on the target cells of the lesion in the vascular system, wherein the ligand is an antibody or an antibody fragment specific to the antigen selected from the group consisting of tumor surface antigen;

tumor endothelial antigen;

non-tumor endothelial antigen;

tumor vessel wall antigen;

neointimal antigens;

arterial plaque antigens; and

vascular smooth muscle cell antigens; and

irradiating at least a portion of the subject with light at a wavelength absorbed by the photosensitizing agent, wherein;

the light is provided by a light source that is external to the intact body of the subject;

the irradiation is at a rate of between about 5 and 100mW/cm² and results in the activation of the photosensitizing agent; and

the photosensitizing agent is cleared from the skin and subcutaneous tissues of the subject prior to the irradiation; and

wherein the duration of radiation exposure is between about 2 hours and 24 hours and the total light dose is between 500 J/cm2 and 10000 J/cm2.

3. The method of claim 1 or 2, wherein said light source is selected from the group consisting of one or a plurality of:

laser diodes, fiber lasers, LEDs, non-laser light source, cold cathode fluorescent tube, incandescent lights, halogen lights, polymeric luminescent devices, fluorescent lights, discharge lamps, and electroluminescent devices.

4. The method of claim 1 or 2, wherein said light is directed through the skin in a direction parallel and lengthwise to the wall of a vascular vessel having the lesion.

5. The method of claim 3, wherein said laser diode is coupled to an optical fiber, and wherein said optical fiber directs said light lengthwise to the vessel wall having the lesion.

6. The method of claim 3, wherein said light emitting diode is a light emitting diode strip, and wherein said light emitting diode strip is placed over the skin overlying the lesion.

7. The method of claim 5, wherein said optical fiber diffuses said light when placed over the vessel wall having the lesion.

8. The method of claim 5, wherein said light source is a mat comprising a plurality of said optical fiber.

9. The method of claim 1 or 2, wherein:

the photosensitizing agent absorbs light in a range of 600 nm-1100 nm; and

the agent is delivered as a delivery system.

10. The method of claim 1 or 2, wherein said wavelength is from about 600 nm to about 1100 nm.

11. The method of claim 10, wherein said wavelength is greater than about 700 nm.

12. The method of claim 11, wherein said light results in a single photon absorption mode by the photosensitizing agent.

13. The method of claim 9, wherein said complex is administered intravenously.

15. The method of claim 9, wherein the photosensitizing agent delivery system comprises a liposome delivery system.

16. The method of claim 1 or 2, wherein said light source is pulse modulated to maximize depth of tissue penetration and minimize heat generation and power consumption.

18. The method of claim 9, wherein the photosensitizing agent is selected from the group consisting of chlorins, bacteriochlorins, phthalocyanines, porphyrins, purpurins, merocyanines, psoralens, benzoporphyrin derivatives (BPD), porfimer sodium, aminolevulinic acid, indocyanine green, methylene blue, toluidine blue and texaphyrins.

2. A method for destroying or impairing target cells of a lesion in the arterial vascular system in a mammalian subject, comprising:

administering to the subject a therapeutically effective amount of a first conjugate comprising a first member of a ligand-receptor binding pair conjugated to an antibody or antibody fragment, wherein the antibody or antibody fragment selectively binds to an antigen on the target cells of the lesion in the arterial vascular system, wherein said antigen selected from the group consisting of tumor surface antigen;

tumor endothelial antigen;

non-tumor endothelial antigen;

tumor vessel wall antigen;

neointimal antigens;

arterial plaque antigens; and

vascular smooth muscle cell antigens;

administering to the subject a therapeutically effective amount of a second conjugate comprising a second member of the ligand-receptor binding pair conjugated to a photosensitizing agent or photosensitizing agent delivery system, wherein the first member binds to the second member of the ligand-receptor binding pair; and

irradiating at least a portion of the subject with light at a wavelength absorbed by the photosensitizing agent, wherein the light is provided by a light source that is external to the subject, wherein the irradiation is between about 5 and 100 mW/cm² and that results in the activation of the photosensitizing agent or prodrug product; and

wherein the duration of radiation exposure is between about 2 hours and 24 hours and the total light dose is between 500 J/cm2 and 10000 J/cm2.

14. The method of claim 2, wherein said ligand-receptor binding pair is selected from the group consisting of:

biotin-streptavidin;

chemokine-chemokine receptor;

growth factor-growth factor receptor; and

antigen-antibody.

17. The method of claim 2, further comprising administering to the subject a liposome delivery system separately conjugated to the second member of the ligand-receptor binding pair.